# US 2015/0104832 A1 · Method for modulating gene expression by modifying the cpg content

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104832 A1
- Document ID: US20150104832A1
- Status: Published application
- Kind: A1
- Application number: 14/483,142
- Filed: 2014-09-10
- Published: 2015-04-16
- Earliest claimed: 2004-08-03
- Assignees: Geneart AG
- Applicants: Geneart AG
- Inventors: FRANK NOTKA; MARCUS GRAF; DORIS LEIKAM; RALF WAGNER; DAVID RAAB
- Web page: https://patentgrep.com/patent/US20150104832A1

## CPC

- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C07K 14/43595: {from coelenteratae, e.g. medusae}
- C12N 2830/46: elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention relates to nucleic acid modifications for a directed expression modulation by the targeted insertion or removal of CpG dinucleotides. The invention also relates to modified nucleic acids and expression vectors.

## Claims

### Claim 1

Method for the targeted modulation of the gene expression, comprising the steps:
(i) Provision of a target nucleic acid sequence to be expressed,
(ii) Modification of the target nucleic acid sequence, in which the number of CpG dinucleotides present in the target nucleic acid sequence is raised using the degeneracy of the genetic code to increase the gene expression, or is lowered to reduce the gene expression,
(iii) Cloning of the thereby modified target nucleic acid sequence with a modified number of the CpG dinucleotides in a suitable expression vector in operative coupling with a suitable transcription control sequence,
(iv) Expression of the modified target nucleic acid sequence in a suitable expression system.

### Claim 2 (depends on 1)

Method according to claim 1, in which in step (ii) the modification of the target nucleic acid sequence is carried out so that, in addition to increasing or reducing the number of CpG dinucleotides, one or more additional modifications is/are carried out at the nucleic acid level.

### Claim 3 (depends on 2)

Method according to claim 2, in which the additional modifications at the nucleic acid level are selected from the group consisting of: alteration of the codon choice, insertion or elimination of sequences stabilising the RNA secondary structure, regions with increased self-homology, regions with increased homology to the natural gene, RNA-instability motifs, splice-activating motifs, polyadenylation motifs, adenine-rich motifs, endonucleose recognition sites.

### Claim 4 (depends on 1)

Method according to claim 1, in which the modification of the target nucleic acid sequence by increasing or reducing the number of CpG dinucleotides is carried out having regard to a codon choice optimised for the expression system.

### Claim at position 5

5-7. (canceled)

### Claim 8 (depends on 1)

Method according to claim 1, in which the target nucleic acid sequence to be expressed is heterologous to the expression system.

### Claim 9 (depends on 1)

Method according to claim 1, in which a eukaryotic or prokaryotic expression system is used as the expression system.

### Claim 10 (depends on 1)

Method according to claim 1, in which as expression system a cell is used selected from the group consisting of prokaryotic cells and eukaryotic cells selected from the group consisting of bacteria, yeast, single cells, parasitic cells, plant cells, insect cells, mammalian cells, human cells and somatic cells, or a cell-free expression environment.

### Claim at position 9

11-22. (canceled)

### Claim 23

Modified nucleic acid with a region capable of transcription that can be expressed in an expression system, and which is derived from a wild-type sequence, in which the region capable of transcription is modified so that it is codon-optimised in relation to the employed expression system, and so that the number of CpG dinucleotides is increased compared to the codon-optimised sequence derived from the wild-type sequence, by using the degeneracy of the genetic code.

### Claim 24 (depends on 23)

Nucleic acid according to claim 23, in which the number of CpG dinucleotides is increased compared to the wild-type sequence by at least 10%, preferably at least 25%, more preferably at least 50%, particularly preferably at least 100%, more particularly preferably at least 200%, especially by a factor of 5 and most especially by a factor of 10 or more.

### Claim 25 (depends on 23)

Nucleic acid according to claim 23, in which the nucleic acid is not associated with a CpG island.

### Claim 26 (depends on 23)

Nucleic acid according to claim 23, comprising a sequence selected from: SEQ ID NOs. 1, 5, 7, 9, 11, 13, 17, 19, 26, 52 and 54.

### Claim 27 (depends on 23)

Vector comprising a nucleic acid according to claim 23 in operative coupling with a suitable transcription control sequence.

### Claim 28 (depends on 27)

Vector according to claim 27, in which the transcription control sequence comprises a promoter.

### Claim 29 (depends on 28)

Vector according to claim 28, in which the promoter is a constitutively active promoter.

### Claim 30 (depends on 29)

Vector according to claim 29, in which the constitutively active promoter is selected from (cytomegalovirus) CMV promoter and Simian virus 40 (SV40) promoter.

### Claim 31 (depends on 28)

Vector according to claim 28, in which the promoter is an inducible promoter.

### Claim 32 (depends on 31)

Vector according to claim 31, in which the inducible promoter is a tetracyclin-dependent promoter.

### Claim 33 (depends on 27)

Vector according to claim 27, in which the promoter is not associated with a CpG island.

### Claim 34 (depends on 23, 27)

Vector according to claim 27, in which the sequences or parts thereof present on the vector and different from the nucleic acid according to claim 23, have a reduced number of CpG dinucleotides.

### Claim 35

(canceled)

### Claim 36 (depends on 27)

Vector according to claim 27, with the nucleic acid sequence shown in SEQ 10 NO. 25.

### Claim at position 24

37-42. (canceled)
